Evidence for immunomodulating supplements in sepsis: A systematic review of the recent evidence

Dr Gordon S. Doig, Associate Professor in Intensive Care, Northern Clinical School Intensive Care Research Unit, University of Sydney, Sydney, Australia www.EvidenceBased.net/Research gdoig@med.usyd.edu.au



© 2013, University of Sydney, Not for reproduction or distribution without permission.



Potential conflicts Gordon S. Doig

Relevant financial relationships with a commercial interest:

- Fresenius Kabi, Academic Research Grants (Past), Consultant and Speaker's Honoraria (Current)
- Baxter Healthcare, Academic Research Grant (Current), Consultant and Speaker's Honoraria (Current)
- Nestle Healthcare, Academic Research Grant (Current), Consultant and Speaker's Honoraria (Current)



Overview

- Arginine in sepsis
- Glutamine in sepsis
- Omega-3 fatty acids in sepsis
- Selenium in sepsis



Literature search

Intensive Care Medicine December 2003, Volume 29, Issue 12, pp 2119-2127

Efficient literature searching: a core skill for the practice of evidence-based medicine

Gordon Stuart Doig, Fiona Simpson

Download PDF (832 KB)









| S NCBI Resources 🗹 How To 🖸 | | <u>Sign in to NC</u> | <u>) BI</u> |
|--|--|---|-------------|
| Public ed.gov PubMed US National Library of Medicine National Institutes of Health Advanced | | Search | elp |
| MEDLINE, life science j | e than 23 million citations for biomedical literature from ournals, and online books. Citations may include links to full led Central and publisher web sites. | PubReader A whole new way to read scientific literature at PubMed Central | |
| Using PubMed | PubMed Tools | More Resources | |
| PubMed Quick Start Guide | PubMed Mobile | MeSH Database | |
| Full Text Articles | Single Citation Matcher | Journals in NCBI Databases | |
| PubMed FAQs | Batch Citation Matcher | Clinical Trials | |
| PubMed Tutorials | Clinical Queries | <u>E-Utilities</u> | |
| New and Noteworthy | Topic-Specific Queries | LinkOut | |



www.EvidenceBased.net





www.EvidenceBased.net





www.Evidencebased.net





www.Evidencebased.net





www.Evidencebased.net





| S NCBI Resources 🖸 How To 🖸 | | Sign in to NCBI |
|---|---|---|
| Public d.gov PubMed US National Library of Medicine National Institutes of Health Advanced | | Search Help |
| MEDLINE, life science | ore than 23 million citations for biomedical literature from a journals, and online books. Citations may include links to full Med Central and publisher web sites. | PubReader A whole new way to read scientific literature at PubMed Central |
| Using PubMed | PubMed Tools | More Resources |
| PubMed Quick Start Guide | PubMed Mobile | MeSH Database |
| Full Text Articles | Single Citation Matcher | Journals in NCBI Databases |
| PubMed FAQs | Batch Citation Matcher | Clinical Trials |
| PubMed Tutorials | Clinical Queries | <u>E-Utilities</u> |
| New and Noteworthy | Topic-Specific Queries | LinkOut |



| S NCBI Resources 🗹 How To 🖸 | | Sign in to NCBI | | | | |
|--|-------------------------|----------------------------|--|--|--|--|
| Public d.gov PubMed US National Library of Medicine National Institutes of Health Advanced | | Search Help | | | | |
| PubMed PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full -text content from PubMed Central and publisher web sites. | | | | | | |
| Using PubMed | PubMed Tools | More Resources | | | | |
| PubMed Quick Start Guide | PubMed Mobile | MeSH Database | | | | |
| Full Text Articles | Single Citation Matcher | Journals in NCBI Databases | | | | |
| PubMed FAQs | Batch Citation Matcher | Clinical Trials | | | | |
| PubMed Tutorials | Clinical Queries | <u>E-Utilities</u> | | | | |
| New and Noteworthy | Topic-Specific Queries | LinkOut | | | | |



| | ces 🗹 H | low To 🖸 | | | | | <u>Sign</u> |
|-------------|------------|--|---|---|--------------------|-------------------------|-------------|
| PubMed Home | More F | Resources 🔻 | Help | | | | |
| bMed Advand | ced Se | arch Builder | | | | You <mark>Tube</mark> T | Tutorial |
| U | se the b | ouilder below to | create your search | | | | |
| Ed | <u>dit</u> | | | | | Clear | |
| | ND 💌 / | All Fields All Fields or <u>Add to histo</u> | | | Show index list | | |
| Hi | story | | | [| Download history C | lear history | |
| 5 | Search | Add to builder | Query | | Items found | Time | |
| ` `` | <u>#1</u> | Add | Search ("intensive care" OR "intensive care units" OR "intensive therapy" OR "critically ill" OR "critical care") | ł | <u>201112</u> | 18:16:48 | |



| S NCBI Resources 🖸 How To 🖸 | | Sign in to NCBI |
|---|---|---|
| Public d.gov PubMed US National Library of Medicine National Institutes of Health Advanced | | Search Help |
| MEDLINE, life science | ore than 23 million citations for biomedical literature from a journals, and online books. Citations may include links to full Med Central and publisher web sites. | PubReader A whole new way to read scientific literature at PubMed Central |
| Using PubMed | PubMed Tools | More Resources |
| PubMed Quick Start Guide | PubMed Mobile | MeSH Database |
| Full Text Articles | Single Citation Matcher | Journals in NCBI Databases |
| PubMed FAQs | Batch Citation Matcher | Clinical Trials |
| PubMed Tutorials | Clinical Queries | <u>E-Utilities</u> |
| New and Noteworthy | Topic-Specific Queries | LinkOut |



| S NCBI Resources 🗹 How To 🗹 | | <u>Sign in to NCBI</u> |
|--|--|---|
| Public gov US National Library of Medicine National Institutes of Health Advanced | | Search Help |
| MEDLINE, life science | re than 23 million citations for biomedical literature from journals, and online books. Citations may include links to full <i>I</i> ed Central and publisher web sites. | PubReader A whole new way to read scientific literature at PubMed Central |
| Using PubMed | PubMed Tools | More Resources |
| PubMed Quick Start Guide | PubMed Mobile | MeSH Database |
| Full Text Articles | Single Citation Matcher | Journals in NCBI Databases |
| PubMed FAQs | Batch Citation Matcher | Clinical Trials |
| PubMed Tutorials | Clinical Queries | <u>E-Utilities</u> |
| New and Noteworthy | Topic-Specific Queries | <u>LinkOut</u> |



SNCBI Resources 🖸 How To 🖸

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For comprehensive searches, use PubMed directly.

Clinical Study Categories

This column displays citations filtered to a specific clinical study category and scope. These search filters were developed by <u>Haynes RB et al.</u> See more <u>filter information</u>.

Systematic Reviews

This column displays citations for systematic reviews, metaanalyses, reviews of clinical trials, evidence-based medicine, consensus development conferences, and guidelines. See filter information or additional related sources.

Medical Genetics

Ø

This column displays citations pertaining to topics in medical genetics. See more <u>filter information</u>.

Search



😪 NCBI 🛛 Resources 🖸 How To 🖸

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For comprehensive searches, use PubMed directly.

#1 sepsis selenium

Clinical Study Categories

This column displays citations filtered to a specific clinical study category and scope. These search filters were developed by <u>Haynes RB et al.</u> See more <u>filter information</u>.

Systematic Reviews

This column displays citations for systematic reviews, metaanalyses, reviews of clinical trials, evidence-based medicine, consensus development conferences, and guidelines. See filter information or additional related sources.

Medical Genetics

Ø

This column displays citations pertaining to topics in medical genetics. See more <u>filter information</u>.

Search



SNCBI Resources 🗹 How To 🖸

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For comprehensive searches, use PubMed directly.

| #1 sepsis selenium Search | | | | | | |
|---|---|---|--|--|--|--|
| Clinical Study Categories | Systematic Reviews | Medical Genetics | | | | |
| Category: Therapy | | Topic: All | | | | |
| Scope: Broad | | | | | | |
| Results: 5 of 38 | Results: 5 of 11 | Results: 2 of 2 | | | | |
| Selenium supplementation for sepsis: a meta-analysis of andomized controlled trials. | Selenium supplementation for sepsis: a meta-analysis of randomized controlled trials. | Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and | | | | |
| Kong Z, Wang F, Ji S, Deng X, Xia Z. | Kong Z, Wang F, Ji S, Deng X, Xia Z. | 2D-LC-MS/MS. | | | | |
| m J Emerg Med. 2013 Aug; 31(8):1170-5. Epub 2013 Jun 21. | Am J Emerg Med. 2013 Aug; 31(8):1170-5. Epub 2013 Jun 21. | Su L, Cao L, Zhou R, Jiang Z, Xiao K, Kong W, Wang H, Deng J, | | | | |
| The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta- | The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta- | Wen B, Tan F, et al. PLoS One. 2013; 8(1):e54237. Epub 2013 Jan 23. Low serum alpha-tocopherol and selenium are associated with accelerated apoptosis in severe sepsis. Weber SUL obmans LE. Schere JC, Thiele JT, Schröder S, Book | | | | |
| nalysis of randomized controlled trials. | analysis of randomized controlled trials. | | | | | |
| Alhazzani W, Jacobi J, Sindi A, Hartog C, Reinhart K, Kokkoris S, Gerlach H, Andrews P, Drabek T, Manzanares W, et al. | Alhazzani W, Jacobi J, Sindi A, Hartog C, Reinhart K, Kokkoris S, Gerlach H, Andrews P, Drabek T, Manzanares W, et al. | | | | | |
| Crit Care Med. 2013 Jun; 41(6):1555-64. | Crit Care Med. 2013 Jun; 41(6):1555-64. | Weber SU, Lehmann LE, Schewe JC, Thiele JT, Schröder S, Book M, Hoeft A, Stüber F. | | | | |



Literature search

- Arginine in sepsis (+ specific critical care terms, in clinical queries)
- Glutamine in sepsis (+ specific critical care terms , in clinical queries)
- Omega-3 fatty acids in sepsis (+ specific critical care terms , in clinical queries)
- Selenium in sepsis (+ specific critical care terms , in clinical queries)





 Arginine availability is reduced in sepsis, which can lead to reduced nitric oxide synthesis, loss of microcirculatory regulation, and enhanced production of superoxide and peroxynitrite.



Arginine in sepsis

 Arginine availability is reduced in sepsis, which can lead to reduced nitric oxide synthesis, loss of microcirculatory regulation, and enhanced production of superoxide and peroxynitrite.

Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GL, Van Buren CT, Rothkopf MM, Daly JM, Adelsberg BR. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med. 1995 Mar;23(3):436-49.
Bertolini G, Iapichino G, Radrizzani D, Facchini R, Simini B, Bruzzone P, Zanforlin G, Tognoni G. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med. 2003 May;29(5):834-40.



Early enteral administration of a formula (Impact Registered Trademark) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: Results of a multicenter, prospective, randomized, clinical trial

Bower, Robert H. MD FACS; Cerra, Frank B. MD FCCM; Bershadsky, Boris PhD MSEE; Licari, Jerome J. PhD; Hoyt, David B. MD FACS; Jensen, Gordon L. MD PhD; Van Buren, Charles T. MD; Rothkopf, Michael M. MD FACP; Daly, John M. MD FACS; Adelsberg, Bernard R. MD FACCP

Patients were randomised to receive:

1) Arginine enhanced EN (Impact) or 2) standard EN

326 patients were enrolled, only 297 were included in analysis

Mortality:

15.5% (23/147) enhanced EN died vs 7.6% (10/132) standard EN

Using Fisher's Exact Test, mortality was significantly increased in patients receiving the arginine supplemented EN (P=0.045).

Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GL, Van Buren CT, Rothkopf MM, Daly JM, Adelsberg BR. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med. 1995 Mar;23(3):436-49.



Guido Bertolini Gaetano Iapichino Danilo Radrizzani Rebecca Facchini Bruno Simini Paola Bruzzone Giancarlo Zanforlin Gianni Tognoni

Early enteral immunonutrition in patients with severe sepsis

Results of an interim analysis of a randomized multicentre clinical trial

Patients were randomised to receive:

1) Arginine enhanced EN (Perative) or 2) standard PN

Interim analysis conducted after 237 patients enrolled. Subgroup analysis planned for septic patients.

 Table 3 Summary of results. (ARD Absolute risk difference, ICU Intensive care unit, EN Enteral nutrition, PN Parenteral nutrition, MH

 Mantel-Haenszel chi-squared test)

| | Mortality in patients with sever sepsis | | | | | | |
|-----------------------------------|---|------------------------|-------------------------------------|----------------|----------------|--|--|
| | EN (<i>n</i> =18) | PN (<i>n</i> =21) | PN (<i>n</i> =21) | | | | |
| | n (%) | ARD (95% CI) | | МН | Fisher test | | |
| ICU mortality 28-day mortality | 8 (44.4%) 8 (44.4%) | 3 (14.3%) 5 (23.8%) | 30.1 (1.5-58.7) 20.6 (-9.4-50.6) | 0.039 0.179 | 0.072 0.196 | | |

Bertolini G, Iapichino G, Radrizzani D, Facchini R, Simini B, Bruzzone P, Zanforlin G, Tognoni G. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med. 2003 May;29(5):834-40.



Glutamine in sepsis

- Glutamine levels are reduced during critical illness.
- Exogenous supplementation can improve gut mucosal atrophy and permeability, possibly leading to reduced bacterial translocation.
- Other potential benefits include enhanced immune cell function, decreased proinflammatory cytokine production, and higher levels of glutathione and antioxidative capacity.



Glutamine in sepsis

- Glutamine levels are reduced during critical illness.
- Exogenous supplementation can improve gut mucosal atrophy and permeability, possibly leading to reduced bacterial translocation.
- Other potential benefits include enhanced immune cell function, decreased proinflammatory cytokine production, and higher levels of glutathione and antioxidative capacity.

- Fuentes-Orozco C, Anaya-Prado R, Gonzalez-Ojeda A et al. L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. *Clin Nutr* **2004**;23:13–21
- Beale RJ, Sherry T, Lei K et al. Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. *Crit Care Med* **2008**;36:131–144
- Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG; Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. *N Engl J Med.* **2013** Apr 18;368(16):1489-97.





• Two small trials (33 patients and 55 patients) conducted in septic populations failed to demonstrate mortality benefits.

Fuentes-Orozco C, Anaya-Prado R, Gonzalez-Ojeda A et al. L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. *Clin Nutr* **2004**;23:13–21

Beale RJ, Sherry T, Lei K et al. Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. *Crit Care Med* **2008**;36:131–144



Glutamine in sepsis

- Two small trials (33 patients and 55 patients) conducted in septic populations failed to demonstrate mortality benefits.
- Due to excess mortality demonstrated in the most recent large scale trial conducted in critically ill patients, use of glutamine in patients with multiple organ dysfunction syndrome, especially renal dysfunction, is warranted.

- Fuentes-Orozco C, Anaya-Prado R, Gonzalez-Ojeda A et al. L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. *Clin Nutr* **2004**;23:13–21
- Beale RJ, Sherry T, Lei K et al. Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. *Crit Care Med* **2008**;36:131–144
- Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG; Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. *N Engl J Med*. **2013** Apr 18;368(16):1489-97.





The omega-3 fatty acids eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) are eicosanoid precursors.





The omega-3 fatty acids eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) are eicosanoid precursors.

The prostaglandins, leukotrienes, and thromboxanes produced from EPA/GLA are less potent than their arachidonic acid-derived equivalents, reducing the proinflammatory impact on the immune response

Ott J, Hiesgen C and Mayer K. Lipids in critical care medicine. *Prostaglandins, Leukotrienes and Essential Fatty Acids* **2011**;85:267-273.









- Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. *Crit Care Med.* **2006** Sep;34(9):2325-33.
- Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study. *Crit Care*. **2011** Jun 9;15(3):R144.



Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials

Oscar D. Rangel-Huerta, Concepcion M. Aguilera, Maria D. Mesa and Angel Gil*

Department of Biochemistry and Molecular Biology Molecular II, Institute of Nutrition and Food Technology, Jose Mataix Biomedical Research Centre, University of Granada, Granada, Spain



Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials

Oscar D. Rangel-Huerta, Concepcion M. Aguilera, Maria D. Mesa and Angel Gil*

Department of Biochemistry and Molecular Biology Molecular II, Institute of Nutrition and Food Technology, Jose Mataix Biomedical Research Centre, University of Granada, Granada, Spain

| Author (Country) | CONSORT Score | Participants/Type of Pathology/Age | RCT Type | Dose/Period | Outcome | Conclusions |
|--|------------------|--|--------------------------------|---|--|--|
| Barbosa <i>et al.</i> (2010) UK | E | <i>n</i> 23; (Exptal = 10; Control = 13); Sepsis (32–80 years) | Randomised, single-blinded. | 6.4 g/d fish oil (Average 1.6 g EPA/day + 0.7 g DHA/ day); 5 days | PGE ₂ , Leukotriene, IL-1β, IL-6, IL-10 and TNF-α. | Inclusion of fish oil in parenteral nutrition of septic ICU patients increases plasma EPA, modifies inflammatory cytokine concentration and improves gas exchange. |
| Mayer <i>et al.</i> (2003) Germany | VG | n 10; (Exptal = 5; Control = 5); Septic shock (31-71 years) | Randomised, open label. | EPA = 5·2-11·2g + DHA = 5·6-12·4g; 10 days (See note 2) | CRP, Leukocytes. | Omega-3 and omega-6 lipid emulsions differentially influence the plasma free fatty acid profile with impact on neutrophil functions. |
| Mayer <i>et al.</i> (2003) Germany | VG | n 21; (Exptal = Control = 6) Sepsis (>18 years) | Randomised, open label. | EPA = 4·55-9·8g/d + DHA = 4·9-10·9g/d; 5 days (See note 3) | IL-1β, IL-6, IL-8, IL-10, TNF-α, | Use of lipid infusions and intravenous feeding have differential impact on inflammatory events. |



Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials

Oscar D. Rangel-Huerta, Concepcion M. Aguilera, Maria D. Mesa and Angel Gil*

Department of Biochemistry and Molecular Biology Molecular II, Institute of Nutrition and Food Technology, Jose Mataix Biomedical Research Centre, University of Granada, Granada, Spain

| Author (Country) | CONSORT Score | Participants/Type of Pathology/Age | RCT Type | Dose/Period | Outcome | Conclusions |
|--|------------------|--|--------------------------------|---|--|--|
| Barbosa <i>et al.</i> (2010) UK | E | <i>n</i> 23; (Exptal = 10; Control = 13); Sepsis (32-80 years) | Randomised, single-blinded. | 6.4 g/d fish oil (Average 1.6 g EPA/day + 0.7 g DHA/ day); 5 days | PGE ₂ , Leukotriene, IL-1β, IL-6, IL-10 and TNF-α. | Inclusion of fish oil in parenteral nutrition of septic ICU patients increases plasma EPA, modifies inflammatory cytokine concentration and improves gas exchange. |
| Mayer <i>et al.</i> (2003) Germany | VG | n 10; (Exptal = 5; Control = 5); Septic shock (31-71 years) | Randomised, open label. | EPA = 5.2 - 11.2 g + DHA = 5.6 - 12.4 g; 10 days (See note 2) | CRP, Leukocytes. | Omega-3 and omega-6 lipid emulsions differentially influence the plasma free fatty acid profile with impact on neutrophil functions. |
| Mayer <i>et al.</i> (2003) Germany | VG | n 21; (Exptal = Control = 6) Sepsis (>18 years) | Randomised, open label. | EPA = 4.55-9.8g/d + DHA = 4.9-10.9g/d; 5 days (See note 3) | IL-1β, IL-6, IL-8, IL-10, TNF-α, | Use of lipid infusions and intravenous feeding have differential impact on inflammatory events. |

- Omega-3 FAs significantly reduced IL-6, increased IL-10 and improved gas exchange.
- No comments on mortality or other patient oriented outcomes.

Effects of enteral feeding with eicosapentaenoic acid, γ -linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock*

Alessandro Pontes-Arruda, MD, PhD; Afra Maria Albuquerque Aragão, RD; Juliana Deusdará Albuquerque, RD

Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006 Sep;34(9):2325-33.

Effects of enteral feeding with eicosapentaenoic acid, γ -linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock*

Alessandro Pontes-Arruda, MD, PhD; Afra Maria Albuquerque Aragão, RD; Juliana Deusdará Albuquerque, RD

A total of 165 patients were recruited.

- 62 patients (37.6% of all enrolled patients) were excluded from analysis due to protocol violations.
- Outcomes are not reported on these 62 patients.

Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006 Sep;34(9):2325-33.
Effects of enteral feeding with eicosapentaenoic acid, γ -linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock*

Alessandro Pontes-Arruda, MD, PhD; Afra Maria Albuquerque Aragão, RD; Juliana Deusdará Albuquerque, RD

A total of 165 patients were recruited.

- 62 patients (37.6% of all enrolled patients) were excluded from analysis due to protocol violations.
- Outcomes are not reported on these 62 patients.

Although this trial reported a significant reduction in mortality in the 103 'evaluable' patients, due to failure to report outcomes on a large number of patients with protocol violations, confirmation in a subsequent trial was required before clinical recommendations could be made.

Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006 Sep;34(9):2325-33.

Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group.

Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Avenida Francisco Sá, 5445, Fortaleza, Ceará, 60,30-002, Brazil. pontes-arruda@secrel.com.br

Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group.

Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Avenida Francisco Sá, 5445, Fortaleza, Ceará, 60,30-002, Brazil. pontes-arruda@secrel.com.br

A total of 115 patients were recruited from 5 sites in Brazil.

Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group.

Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Avenida Francisco Sá, 5445, Fortaleza, Ceará, 60,30-002, Brazil. pontes-arruda@secrel.com.br

A total of 115 patients were recruited from 5 sites in Brazil.

• ITT analysis demonstrated reduced progression to more severe sepsis in patients receiving the study diet (Oxepa).

Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group.

Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Avenida Francisco Sá, 5445, Fortaleza, Ceará, 60,30-002, Brazil. pontes-arruda@secrel.com.br

A total of 115 patients were recruited from 5 sites in Brazil.

- ITT analysis demonstrated reduced progression to more severe sepsis in patients receiving the study diet (Oxepa).
- Also significantly less respiratory failure and cardiovascular failure (based on organ dysfunction scores) with study diet.

Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group.

Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Avenida Francisco Sá, 5445, Fortaleza, Ceará, 60,30-002, Brazil. pontes-arruda@secrel.com.br

A total of 115 patients were recruited from 5 sites in Brazil.

- ITT analysis demonstrated reduced progression to more severe sepsis in patients receiving the study diet (Oxepa).
- Also significantly less respiratory failure and cardiovascular failure (based on organ dysfunction scores) with study diet.
- Duration of ventilation was reduced, and ICU free days and hospital free days were increased in study diet patients.

Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group.

Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Avenida Francisco Sá, 5445, Fortaleza, Ceará, 60,30-002, Brazil. pontes-arruda@secrel.com.br

A total of 115 patients were recruited from 5 sites in Brazil.

- ITT analysis demonstrated reduced progression to more severe sepsis in patients receiving the study diet (Oxepa).
- Also significantly less respiratory failure and cardiovascular failure (based on organ dysfunction scores) with study diet.
- Duration of ventilation was reduced, and ICU free days and hospital free days were increased in study diet patients.
- There was no difference in mortality between groups.

Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group.

Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Avenida Francisco Sá, 5445, Fortaleza, Ceará, 60,30-002, Brazil. pontes-arruda@secrel.com.br

A total of 115 patients were recruited from 5 sites in Brazil.

- ITT analysis demonstrated reduced progression to more severe sepsis in patients receiving the study diet (Oxepa).
- Also significantly less respiratory failure and cardiovascular failure (based on organ dysfunction scores) with study diet.
- Duration of ventilation was reduced, and ICU free days and hospital free days were increased in study diet patients.
- There was no difference in mortality between groups.

Although these results were interesting, they did not confirm the findings of the 2006 trial. Due to the small size of this trial, clinical recommendations cannot be made. More research is needed.



Selenium in Sepsis

- Selenium could be beneficial in sepsis through reversible inhibition of NF-κB binding to DNA, cytokine production blockade, or apoptosis induction in proinflammatory cells.
- Critically ill patients with systematic inflammatory response syndrome (SIRS) and severe sepsis were found to have 40% lower selenium levels compared to critically ill patients without SIRS or severe sepsis.

Kong Z, Wang F, Ji S, Deng X, Xia Z. Selenium supplementation for sepsis: a meta-analysis of randomized controlled trials. *Am J Emerg Med.* **2013** Aug;31(8):1170-5



Selenium in Sepsis

| | Se | | Control | | | Risk Ratio | Risk Ratio |
|---|-------------------|-------|--|-------|--------|-------------------|--------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% C | M-H, Fixed, 95% Cl |
| J Valenta 2011 | 19 | 75 | 24 | 75 | 19.4% | 0.79 [0.48, 1.32] | |
| MW Angstwurm 1999 | 11 | 21 | 9 | 21 | 7.3% | 1.22 [0.64, 2.32] | |
| MW Angstwurm 2007 | 46 | 116 | 61 | 122 | 48.1% | 0.79 [0.60, 1.06] | -# |
| V Mashra 2007 | 11 | 18 | 15 | 22 | 10.9% | 0.90 [0.56, 1.43] | |
| X Forceville 2007 | 21 | 31 | 17 | 29 | 14.2% | 1.16 [0.78, 1.71] | |
| Total (95% CI) | | 261 | | 269 | 100.0% | 0.89 [0.73, 1.07] | • |
| Total events | 108 | | 126 | | | | |
| Heterogeneity: Chi² = 3.51, df = 4 (<i>P</i> = .48); l² = 0% | | | | | | | |
| Test for overall effect: Z | = 1.25 (<i>P</i> | | 0.1 0.2 0.5 1 2 5 10 Favours Se Favours Control | | | | |

Fig. 3. Summary of relative risks of all-cause mortality in septic patients between the selenium group and the control group.

Kong Z, Wang F, Ji S, Deng X, Xia Z. Selenium supplementation for sepsis: a meta-analysis of randomized controlled trials. *Am J Emerg Med.* **2013** Aug;31(8):1170-5



| | Seleni | um | Place | bo | | | |
|-------------------|--------|-------|--------|-------|--------|---------------------|------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | Year |
| Zimmermann 1997 | 3 | 20 | 8 | 20 | 3.8% | 0.26 [0.06, 1.21] | 1997 |
| Angstwurm 1999 | 7 | 21 | 11 | 21 | 5.6% | 0.45 [0.13, 1.58] | 1999 |
| Angstwurm 2007 | 46 | 116 | 61 | 122 | 32.9% | 0.66 [0.39, 1.10] | 2007 |
| Mishra 2007 | 11 | 18 | 15 | 22 | 5.1% | 0.73 [0.20, 2.70] | 2007 |
| Forceville 2007 | 14 | 31 | 13 | 29 | 8.4% | 1.01 [0.37, 2.80] | 2007 |
| Montoya 2009 | 6 | 34 | 8 | 34 | 6.2% | 0.70 [0.21, 2.28] | 2009 |
| Valenta 2011 | 19 | 75 | 24 | 75 | 17.2% | 0.72 [0.35, 1.47] | 2011 |
| Manzanares 2011 | 3 | 12 | 4 | 10 | 2.6% | 0.50 [0.08, 3.08] | 2011 |
| Andrews 2011 | 30 | 67 | 27 | 65 | 18.3% | 1.14 [0.57, 2.27] | 2011 |



| | Selenium | | Placebo | | | | |
|-------------------|----------|-------|---------|-------|--------|---------------------|------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | Year |
| Zimmermann 1997 | 3 | 20 | 8 | 20 | 3.8% | 0.26 [0.06, 1.21] | 1997 |
| Angstwurm 1999 | 7 | 21 | 11 | 21 | 5.6% | 0.45 [0.13, 1.58] | 1999 |
| Angstwurm 2007 | 46 | 116 | 61 | 122 | 32.9% | 0.66 [0.39, 1.10] | 2007 |
| Mishra 2007 | 11 | 18 | 15 | 22 | 5.1% | 0.73 [0.20, 2.70] | 2007 |
| Forceville 2007 | 14 | 31 | 13 | 29 | 8.4% | 1.01 [0.37, 2.80] | 2007 |
| Montoya 2009 | 6 | 34 | 8 | 34 | 6.2% | 0.70 [0.21, 2.28] | 2009 |
| Valenta 2011 | 19 | 75 | 24 | 75 | 17.2% | 0.72 [0.35, 1.47] | 2011 |
| Manzanares 2011 | 3 | 12 | 4 | 10 | 2.6% | 0.50 [0.08, 3.08] | 2011 |
| Andrews 2011 | 30 | 67 | 27 | 65 | 18.3% | 1.14 [0.57, 2.27] | 2011 |



| | Selenium Placebo | | | oo | | Odds Ratio | | |
|-------------------|------------------|-------|--------|-------|--------|---------------------|-------|---------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | Year | _ |
| Zimmermann 1997 | 3 | 20 | 8 | 20 | 3.8% | 0.26 [0.06, 1.21] | 1997 | |
| Angstwurm 1999 | 7 | 21 | 11 | 21 | 5.6% | 0.45 [0.13, 1.58] | 1999 | |
| Angstwurm 2007 | 46 | 116 | 61 | 122 | 32.9% | 0.66 [0.39, 1.10] | 2007 | |
| 🗸 Mishra 2007 | 11 | 18 | 15 | 22 | 5.1% | 0.73 [0.20, 2.70] | 2007 | |
| Forceville 2007 | 14 | 31 | 13 | 29 | 8.4% | 1.01 [0.37, 2.80] | 2007 | |
| Montoya 2009 | 6 | 34 | 8 | 34 | 6.2% | 0.70 [0.21, 2.28] | 2009 | |
| Valenta 2011 | 19 | 75 | 24 | 75 | 17.2% | 0.72 [0.35, 1.47] | 2011 | |
| 🗸 Manzanares 2011 | 3 | 12 | 4 | 10 | 2.6% | 0.50 [0.08, 3.08] | 2011 | Subgroup data |
| Andrews 2011 | 30 | 67 | 27 | 65 | 18.3% | 1.14 [0.57, 2.27] | 2011 | Subgroup data |
| T | he au | thor | s of t | wo t | trials | kindly provide | ed us | with data on |
| the sul | bgrou | ip of | f pati | ents | with | sepsis, which w | ve in | cluded in the |
| prima | ry ana | alysi | s (17, | , 26) | • | | | |



| | Seleni | um | Place | bo | | Odds Ratio | | |
|-------------------|--------|-------|--------|-------|--------|---------------------|------|---------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | Year | _ |
| Zimmermann 1997 | 3 | 20 | 8 | 20 | 3.8% | 0.26 [0.06, 1.21] | 1997 | German |
| Angstwurm 1999 | 7 | 21 | 11 | 21 | 5.6% | 0.45 [0.13, 1.58] | 1999 | |
| Angstwurm 2007 | 46 | 116 | 61 | 122 | 32.9% | 0.66 [0.39, 1.10] | 2007 | |
| Mishra 2007 | 11 | 18 | 15 | 22 | 5.1% | 0.73 [0.20, 2.70] | 2007 | |
| Forceville 2007 | 14 | 31 | 13 | 29 | 8.4% | 1.01 [0.37, 2.80] | 2007 | |
| Montoya 2009 | 6 | 34 | 8 | 34 | 6.2% | 0.70 [0.21, 2.28] | 2009 | Spanish |
| Valenta 2011 | 19 | 75 | 24 | 75 | 17.2% | 0.72 [0.35, 1.47] | 2011 | |
| Manzanares 2011 | 3 | 12 | 4 | 10 | 2.6% | 0.50 [0.08, 3.08] | 2011 | Subgroup data |
| Andrews 2011 | 30 | 67 | 27 | 65 | 18.3% | 1.14 [0.57, 2.27] | 2011 | Subgroup data |



| | Seleni | um | Placebo | | Odds Ratio | | Odds Ratio | |
|---|--------|-------|---------|-------|------------|--|------------|---------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | Year | M-H, Random, 95% CI |
| Zimmermann 1997 | 3 | 20 | 8 | 20 | 3.8% | 0.26 [0.06, 1.21] | 1997 | |
| Angstwurm 1999 | 7 | 21 | 11 | 21 | 5.6% | 0.45 [0.13, 1.58] | 1999 | |
| Angstwurm 2007 | 46 | 116 | 61 | 122 | 32.9% | 0.66 [0.39, 1.10] | 2007 | |
| Mishra 2007 | 11 | 18 | 15 | 22 | 5.1% | 0.73 [0.20, 2.70] | 2007 | |
| ✓ Forceville 2007 | 14 | 31 | 13 | 29 | 8.4% | 1.01 [0.37, 2.80] | 2007 | |
| Montoya 2009 | 6 | 34 | 8 | 34 | 6.2% | 0.70 [0.21, 2.28] | 2009 | |
| Valenta 2011 | 19 | 75 | 24 | 75 | 17.2% | 0.72 [0.35, 1.47] | 2011 | |
| Manzanares 2011 | 3 | 12 | 4 | 10 | 2.6% | 0.50 [0.08, 3.08] | 2011 | |
| Andrews 2011 | 30 | 67 | 27 | 65 | 18.3% | 1.14 [0.57, 2.27] | 2011 | |
| Total (95% CI) | | 394 | | 398 | 100.0% | 0.73 [0.54, 0.98] | | • |
| Total events | 139 | | 171 | | | | | - |
| Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 4.61$, $df = 8$ (P = 0.80); $I^2 = 0\%$ | | | | | | | | |
| Test for overall effect: | | - | | | | 0.02 0.1 1 10 50 Favours Selenium Favours Placebo | | |





Selenium in Sepsis

| | | | Example: "Heart attack" AND "Los Angeles" | | | | | |
|---|---|---------------------------|---|------------------|------------|--|--|--|
| ClinicalTrials.gov | | Search for studies: | | | Search | | | |
| A service of the U.S. National Institutes of Health | | | Advanced Search Hel | Studies by Topic | Glossary | | | |
| Find Studies About Clinical Studies | Submit Studies Resources | About This Site | | | | | | |
| Home > Find Studies > Study Record Detail | | | | Те | ext Size 🔻 | | | |
| Placebo Controlled Trial of Sodium S This study has been completed. Sponsor: Kompetenznetz Sepsis Collaborators: Biosyn Brahms AG Information provided by (Responsible Party): Kompetenznetz Sepsis | Selenite and Procalcitonin Gu ClinicalTrials.gov Identifier: NCT00832039 First received: January 28, 2009 Last updated: June 28, 2013 Last verified: June 2013 History of Changes | iided Antimicrobial The | erapy in Severe Se | psis (SISPCT) | | | | |
| Full Text View Tabular View No St | tudy Results Posted Disclaimer | P How to Read a Study Rec | ord | | | | | |

- Planned to recruit 1,180 patients.
- Recorded as 'completed' in June 2013.
- May only have recruited 380 patients?



Selenium in Sepsis

In the mean time:

- Selenium is relatively cheap.
- Sepsis carries a high risk of mortality.
- Although the authors report concerns about the analytic metrics used with the results being very close to 0.05 with Relative Risk and more significant when an Odds Ratio is used, the Odds Ratio is generally more stable and robust.
- > 500 µgm Selenium per day was associated with a significant reduction in mortality.





- Arginine in sepsis
- Glutamine in sepsis
- Omega-3 fatty acids in sepsis
- Selenium in sepsis



- Arginine in sepsis
 - Clinical recommendations cannot be made
- Glutamine in sepsis
- Omega-3 fatty acids in sepsis
- Selenium in sepsis



- Arginine in sepsis
 - Clinical recommendations cannot be made
- Glutamine in sepsis
 - Clinical recommendations cannot be made
- Omega-3 fatty acids in sepsis
- Selenium in sepsis



- Arginine in sepsis
 - Clinical recommendations cannot be made
- Glutamine in sepsis
 - Clinical recommendations cannot be made
- Omega-3 fatty acids in sepsis
 - Clinical recommendations cannot be made
- Selenium in sepsis



- Arginine in sepsis
 - Clinical recommendations cannot be made
- Glutamine in sepsis
 - Clinical recommendations cannot be made
- Omega-3 fatty acids in sepsis
 - Clinical recommendations cannot be made
- Selenium in sepsis
 - A well conducted meta-analysis of 9 clinical trials including 792 septic patients demonstrates > 500 µgm Selenium per day was associated with a significant reduction in mortality.



- Arginine in sepsis
 - Clinical recommendations cannot be made
- Glutamine in sepsis
 - Clinical recommendations cannot be made
- Omega-3 fatty acids in sepsis
 - Clinical recommendations cannot be made
- Selenium in sepsis
 - A well conducted meta-analysis of 9 clinical trials including 792 septic patients demonstrates > 500 µgm Selenium per day was associated with a significant reduction in mortality.
 - Read the MA, and individual RCTs, for additional dosing/patient selection details.





- Arginine in sepsis
 - Clinical recommendations cannot be made
- Glutamine in sepsis
 - Clinical recommendations cannot be made
- Omega-3 fatty acids in sepsis
 - Clinical recommendations cannot be made
- Selenium in sepsis
 - A well conducted meta-analysis of 9 clinical trials including 792 septic patients demonstrates > 500 µgm Selenium per day was associated with a significant reduction in mortality.
 - Read the MA, and individual RCTs, for additional dosing/patient selection details.